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expression in restenotic plaques and DCA specimens from diabetic pts. The increased 
expression of PAPP-A in this subset of pts may suggest a mechanism for increased rest- 
enosis in diabetes through alterations in the IGF system. 
1055-25 Coincident Presence of HSP47 and BCL-2 Early 
Postarterial Trauma 
AlexanderJabs, Stefan Kramer, Dirk Skowasch, Berndt Liiderftz. Gerhard Bauriedel, 
Department of Cardio/ogx University of Bonn, Bonn, Germany 
Backgrounct Hypercellular neointima forming in response to angioplasty procedures is 
characterized by de ncvo synthesis of extracellular matrix components and low apoptotic 
cell death. Hence, we sought to analyse antiapoptotic B-cell-lymphoma (Bcl) - 2 protein 
and Heat Shock Protein (HSP) 47, an intracellular marker of collagen synthesis, in neoin- 
timal lesions. 
Methods: Balloon overstretch injury was performed in rat carotid arteries. Protein 
expression was detected by immunohistochemistty in serial sections at different times 
(7d (n=5). 14d (n=6), 26d (n=6)) post angioplasty. Uninjured contralateral carotid arteries 
served as controls. 
Results: Neointima (N) formation was seen 7 days post balloon injury in 4 of 5 treated 
arteries (mean N area 0.012 ~O.O07mm*). Early N tissue showed maximal expression of 
HSP47 (20.7 f 13.6%) and Bcl-2 (25.4 f 14.0%). With growing N area at 26d (ranging 
from 0.016mm’to O,207mm’, mean 0.130 f O.O67mm*), the expression of both proteins 
decreased significantly to 9.3 _t 8.0% (HSP47) and 5.7 f 2.5% (Bcl-2). In the 26d lesions, 
the majority of HSP47 positive cells were located close to the arterial lumen, and only 
sparse signaling was found in deep N layers. Bcl-2 expression was almost exclusively 
detectable in the layer of N cells near the luminal border. HSP47 and Bcl-2 expressions 
correlated in the N compartment (R=0.49, p=O.O4). Interestingly, HSP47 expression lev- 
els in 26d-lesions correlated to the N area quantitated by morphometric analysis 
(R=0.66, p=O.O29). 
Conclusion: Antispoptotic Bcl-2 and the collagen-specific chaperone HSP47 are both 
present and positively correlated in early neointimal lesions. While Bcl-2 might protect 
neointimal cells from cell death, HSP47 modulates the de nova synthesis of neointimal 
collagens. Persistently high HSP47 expression may significantly contribute to restenosis. 
1055-26 a& lntegrin (VLA-4) Blockade Reduces Neointimai 
Growth After Carotid Air Desiccation injury in the ApoE 
(J-) Mouse 
wG. J William Phillips, John M. Sanders, Ann C. Czamik, Klaus F. Ley, 
Ian J. Sarembock, University of Virginia, Charlottesville. Virginia. 
Background: a& integrin (VLA-4) is expressed on leukocytes and promotes inflamma- 
tory cell recruitment via ligation of VCAM-1 expressed on the luminal surface. We 
hypothesized that VLA-4 positive cells are recruited following arterial injury and that VLA- 
4 blockade would reduce neointimal formation following carotid injury in ApoE mice. 
Methods: Female ApoE (-/-) mice fed a WD underwent air desiccation injury of the right 
common carotid artery. Vessels were harvested 3 8 7 days after injury to determine VLA- 
4 expression by immunohistochemistry (IHC). Additional mice received either a VLA-4 
blocking mAb (PSZ) 200 pg ip 1 hour prior to injury (Early PSZ, n=t?) or 200 ug PS2 (Pro- 
longed PSZ. n=@ or isotype control mAb (Isotype, n=7) on days 0,3,7,10 after injury. His- 
tomorphometry was assessed at 26 days. 
Results: IHC revealed recruitment of VLA-4 positive cells early after injury (see table). 
Blockade of VLA-4 resulted in a reduction in neointimal gmwth 26 days after injury (lso- 
type=46,200~10,500 mm*; Early PS2=24,200~7,100 mm’, 50% reduction, p=.O8: Pro- 
longed PS2=13.500+3,200 mm’. 72% reduction, p=.OO5). No difference was seen in 
EEL or media areas. 
Conclusions: Carotid injury results in early recruitment of VLA-4 positive cells to the 
vessel wall. Prolonged VIA-4 blockade resulted in a significant 72% reduction in neointi- 
mal growth 26 days following injury. suggesting an important role for a4p1 integrin (VLA- 
4) in the response to arterial injury. 
Table 1. VLA-4 IHC (36 positive staining) 
Uninjured(nz4) Day 3(n=5) 
4*4 34 f 26 (p=.O7) 
Day 7&S) 
40 f 14 (p=. 005) 
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0032-l 210-Day Follow-up of the RAVEL Study: A Randomized 
Study with the Sirolimus-Eiuting Bx VELOCITYfm 
Balloon-Expandable Stent in the Treatment of Patients 
With De Novo Native Coronary Artery Lesions 
Jean, M. Perin, E. Ban Hayashi, A. Colombo, G. Schuler, P. Barragan, C. Bode. 
J. E. Sousa, M. C. Morice. Patrick W. Serruys, Thoraxcenter, Rottem’am, The 
Netherlands. 
Background: Sirolimus. a naturally occurring macrocyclic antibiotic, is a potent immuno- 
suppressive agent inducing late Gl cell cycle arrest. In a pilot study long-term (12 
months) ultrasonic follow-up (FU) demonstrated a nearfy complete abolition of neointimal 
hyperplasia. The RAVEL is a multicenter, double-blind, randomized study with a two-arm 
design assessing safety and effectiveness of the Sirolimus-eluting Bx VELOCITYb” stent 
versus the uncoated metal Bx VELOCITYtm stent (18 mm). Methods: The primary end- 
point was angiographic late loss at 6 months. The secondary endpoints were major 
adverse cardiac events target vessel revascularization, target lesion revascularization 
(TLR), restenosis rate. Inclusion criteria: patients with stable or unstable angina with sin- 
gle treatment of de nova lesions, < 16mm in length, 2.5-3.5 mm in diameter. Results: 
Between August.2000 and December,ZOOO. 236 patients were included in 19 sites in 
Europe and South America. Baseline demographics and lesion characteristics were 
equally distributed. After a loading dose, Clopidogrel or liclopidine was continued up to 6 
weeks. No acute, subacute or late thrombosis occurred. 
Conclusions: The QCA data demonstrate a near complete abolition of neo-intimal in- 
stent proliferation with zero binary restenosis in the Sirolimus group. This translated clini- 
cally into no TLR and an event-free survival of 97 %. One-year FU data will be presented. 
Resuttr at 210 days 
Reference Diameter (mm) 
MLD Post-procedure (mm) 
MLD Follow-up (mm) 
Late Loss (mm) 
Restenosis rate (%) 
TLR 
Event Free survival 
Sirolimus Control P-value 
2.60 2.64 NS 
2.43 2.41 NS 
2.42 1.64 .OOOl 
-0.01 0.60 .OOOl 
0 26 .OOOl 
0 22 .OOOl 
97 72 .ooOl 
4:15 p.m. 
0032-2 Is Bigger Better With Vascular Brachytherapy (VBT) for 
in-Stent Restenosis? impact of Optimal Final 
Angiographic Results and Predictors of Restenosis in 
990 VBT Patients 
mO. Alexandra J. Lansky, Roxana Mehran, Kartik Desai. Brian 
Proctor, Kazuyuki Shirai, Nishe Dave, Ecatarina Cristea, Martin Fahy, George Dangas, 
Gregg W. Stone, Ron Waksman, Jeffrey Moses, Martin B. Leon, Cardiovascular 
Research Foundation, New York. 
Background: After conventional PCI maximizing the final lumen dimensions predicts 
lower restenosis rates. Whether this ‘“Bigger is Better” strategy applies to pts treated with 
VBT for in-stent restenosis (ISR) is not known. Methods: Procedural and follow-up angio- 
grams of 990 pts enrolled in VBT trials were analyzed prospectively. Pts were treated 
with Gamma (N=370). Beta (N=265) radiation or placebo (N=355) for native coronary 
ISR. Results: Regression analysis was used to construct probability models for “treated 
segment’ restenosis (including edges) (fig 1) and “stent edge’ (Fig 2) restenosis based 
on the final minimal lumen diameter (MLD). Both Beta and Gamma VBT patients had 
increased probability of restenosis with smaller final MLD. By multivariable regression 
analysis independent angiographic predictors of treated segment restsnosis included 
Gamma VBT (OR=0.315, p<O.OOl) and Beta VBT (OR=0.366, pcO.OOl), lesion length 
(OR=1.045, p<O.OOl), vessel size (OR=0.651, p-zO.001) but not final MLD (OR~0.702, 
p=O.O646). Conclusions: Optimizing final angiographic results is associated with a lower 
probability of treated segment restenosis and stent edge restenosis for both Beta and 
Gamma Radiation therapy. However, restenosis after VBT appears more dependent on 
reference vessel size rather than the final treated lesion MLD. 
